Clinical Trials at Dana Farber Cancer Institute

As of August 2026, 209 paid clinical trials are recruiting at Dana Farber Cancer Institute, located at 44 BINNEY ST, BOSTON, MA 02115-6013, phone (617) 632-3497 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 27, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

210 clinical trials at Dana Farber Cancer Institute

·Clear filters·

Get a weekly email when new trials open in Boston, MA.

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

for Chronic Graft-versus-host-disease

Sites in Boston +12 more locations

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 2+

Code: NCT04710576·Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

CAR-T Long Term Follow Up (LTFU) Study

for Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Sites in Boston +40 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 0 - 100

Code: NCT02445222·Phase 3·Recruiting·Listed May 2015

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

Sites in Boston +57 more locations

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

for Glioblastoma (GBM)

Sites in Boston +24 more locations

Sponsor: Black Diamond Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07326566·Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

for Glioblastoma

Sites in Boston +10 more locations

Sponsor: Alpheus Medical, Inc.

Sex: All·Age: 18 - 80

Code: NCT07225621·Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of PHST001 in Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Boston +19 more locations

Sponsor: Pheast Therapeutics

Sex: All·Age: 18+

Code: NCT06840886·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

Sites in Boston +17 more locations

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for Advanced Solid Tumor

Drug: Tulmimetostat

Sites in Boston +6 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04104776·Phase 1, Phase 2·Recruiting·Listed Sep 2019

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for Metastatic Breast Cancer

Sites in Boston +15 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05894239·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

for Solid Tumors

Drug: INCB161734

Sites in Boston +12 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06179160·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

Drug: daraxonrasib

Sites in Boston +19 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for Solid Tumor

Sites in Boston +10 more locations

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06619587·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

for Multiple Myeloma

Drug: Selinexor

Sites in Boston +2 more locations

Sponsor: Karyopharm Therapeutics Inc

Sex: All·Age: 18+

Code: NCT02343042·Phase 1, Phase 2·Recruiting·Listed Jan 2015

Apply to this trial

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for Endometrial Cancer

Sites in Boston +16 more locations

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06293898·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumors

Sites in Boston +10 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05836324·Phase 1·Recruiting·Listed May 2023

Apply to this trial

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

for Squamous Cell Carcinoma of Head and Neck

Drug: Amivantamab

Sites in Boston +13 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06385080·Phase 1, Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Boston +10 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06589596·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

for Ovarian Cancer

Sites in Boston +12 more locations

Sponsor: NextCure, Inc.

Sex: All·Age: 18+

Code: NCT06774963·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

for Non-small Cell Lung Cancer (NSCLC)

Sites in Boston +11 more locations

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT07154706·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

SPEARHEAD-3 Pediatric Study

for Synovial Sarcoma

Sites in Boston +9 more locations

Sponsor: USWM CT, LLC

Sex: All·Age: 2 - 21

Code: NCT05642455·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Boston +12 more locations

Sponsor: Tubulis GmbH

Sex: All·Age: 18+

Code: NCT06657222·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

Sites in Boston +13 more locations

Sponsor: ModernaTX, Inc.

Sex: All·Age: 12+

Code: NCT05533697·Phase 1, Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for Non-small Cell Lung Cancer (NSCLC)

Sites in Boston +20 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05379985·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

for Familial Adenomatous Polyposis (FAP)

Sites in Boston +17 more locations

Sponsor: Rapamycin Holdings Inc.

Sex: All·Age: 18+

Code: NCT06950385·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for Locally Advanced Solid Tumor

Sites in Boston +19 more locations

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05384626·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

for Primary Myelofibrosis

Sites in Boston +12 more locations

Sponsor: Ajax Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06343805·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for Solid Tumor

Sites in Boston +14 more locations

Sponsor: NiKang Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06586957·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for KRAS G12C Mutation

Sites in Boston +10 more locations

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT06720987·Phase 1·Recruiting·Listed Dec 2024

Apply to this trial

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

for Non Small Cell Lung Cancer

Sites in Boston +14 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06810544·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

for Myeloproliferative Neoplasms

Drug: Ruxolitinib

Sites in Boston +12 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06034002·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

for High-risk Myelodysplastic Syndrome

Sites in Boston +10 more locations

Sponsor: Crossbow Therapeutics, Inc.

Sex: All·Age: 12+

Code: NCT06994676·Phase 1·Recruiting·Listed May 2025

Apply to this trial

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

for Relapsed or Refractory T Cell Lymphoma

Sites in Boston +18 more locations

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT05079282·Phase 1·Recruiting·Listed Oct 2021

Apply to this trial

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for Ovarian Cancer

Sites in Boston +13 more locations

Sponsor: OnCusp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06234423·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

for Gastrointestinal Stromal Tumor (GIST)

Sites in Boston +9 more locations

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT06630234·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

for Metastatic Breast Cancer

Drug: Palazestrant

Sites in Boston +13 more locations

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05508906·Phase 1·Recruiting·Listed Aug 2022

Apply to this trial

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

for Solid Tumors

Sites in Boston +16 more locations

Sponsor: ORIC Pharmaceuticals

Sex: All·Age: 18+

Code: NCT05315700·Phase 1, Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

for Relapsed Multiple Myeloma

Sites in Boston +11 more locations

Sponsor: Opna Bio LLC

Sex: All·Age: 18+

Code: NCT06433947·Phase 1·Recruiting·Listed May 2024

Apply to this trial

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

for Locally Advanced Solid Tumor

Sites in Boston +13 more locations

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05732831·Phase 1, Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

for B-cell Acute Lymphoblastic Leukemia

Sites in Boston +12 more locations

Sponsor: Cellectis S.A.

Sex: All·Age: 15 - 50

Code: NCT04150497·Phase 1, Phase 2·Recruiting·Listed Nov 2019

Apply to this trial

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for Advanced NRAS-Mutant Melanoma

Sites in Boston +8 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07584226·Phase 1·Recruiting·Listed May 2026

Apply to this trial